Replies to post #271 on Aptose Biosciences Inc (APTO)

[Tartiaboy]

I believe you are correct that Ven is the main driver of myelosuppression in the Flt3/Ven combos. That said we don't know if lower doses of Ven may be effective in a TUSP/Ven combo. We don't know the dose titration plans for TUSP/Ven yet.

In any event, Gilteritinib and Quizartinib bring other toxicities such as QTc elongation and DS into the combination picture.